Organogenesis

20 total trials 2 currently recruiting 14 completed

Organogenesis sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 14 completed. 8 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Venous Ulcer, with 3 trials.

Trial Pipeline

20 total, page 1 of 1

RECRUITING NA

Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)

NCT07510412
RECRUITING NA

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

NCT06618612
COMPLETED Phase 3

A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

NCT06000410
COMPLETED Phase 3

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

NCT04636229
TERMINATED NA

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

NCT03502824
COMPLETED NA

Affinity Prospective Diabetic Foot Trial Crossover Group

NCT03205436
COMPLETED

The RESPOND Registry

NCT03286452
COMPLETED

Prospective PuraPly™ AM Case Series Study

NCT03070925
COMPLETED

PuraPly™ Antimicrobial Wound Matrix and Wound Management

NCT03070938
COMPLETED NA

Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers

NCT02880592
TERMINATED Phase 1

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

NCT01929954
COMPLETED Phase 4

A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

NCT01327937
COMPLETED Phase 3

Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

NCT00909870
TERMINATED Phase 1

A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage

NCT00679081
COMPLETED Phase 1

A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

NCT00587587
TERMINATED Phase 3

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

NCT00587223
COMPLETED Phase 3

Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration

NCT00587834
COMPLETED NA

A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva

NCT01547962
COMPLETED Phase 3

Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers

NCT01181453
COMPLETED Phase 3

Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers

NCT01181440

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 3 7
Phase 4 1

Therapeutic Areas

Venous Ulcer 3
Diabetic Ulcer 2
Trauma Wounds 2
Surgical Wounds 2
Pressure Ulcer 2
Chronic Vascular Ulcer 1
Draining Wounds 1
Partial Thickness Wound 1
Trauma Wound 1
Diabetic Ulcers 1

What the Pipeline for Organogenesis Shows

According to the ClinicalTrials.gov registry, Organogenesis is linked to 20 US clinical trials across every stage of research activity. Of those, 2 studies are currently recruiting, about 10% of the sponsor's indexed portfolio, and 14 are already marked complete, representing roughly 70% of the total.

The phase mix for Organogenesis reports 8 late-stage studies (Phase 3 and Phase 4 combined) and 3 earlier-phase studies (Phase 1 and Phase 2).

The top therapeutic focus area indexed for Organogenesis is Venous Ulcer with 3 linked trials, and 9 other condition areas appear in the top list above.

How to read these pipeline numbers

Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.